(PharmaNewsWire.Com, March 12, 2021 ) The report “Mice Model Market by Mice Type (Inbred, Knockout), Technology (CRISPR, TALEN, ZFN), Application (Oncology, Diabetes, Immunology), Service (Breeding, Cryopreservation, Genetic testing), Care Products (Cages, Bedding, Feed), Region – Global Forecast to 2025″, size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period. Market growth is driven mainly by the ongoing innovations in mice models, continuous support in the form of investments and grants from the government & private sectors, and increased demand for humanized mice models due to the growing consumption of personalized medicine.
Browse 295 market data Tables and 29 Figures spread through 263 Pages and in-depth TOC on “Mice Model Market – Global Forecast to 2025”
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the mice model market for the research & development of vaccines and antiviral drugs. A large number of animal models are required to verify the safety and efficacy of new entities before conducting human trials. According to the WHO, more than 20 vaccines are being developed across the globe for COVID-19. These vaccines are in the preclinical phase, and some of them have already entered the animal trials phase. Several mice models have supported the replication of SARS-CoV-2, including C57BL/6, BALB/c, 129SvEv, hACE2 transgenic, and STA1 gene knockout (KO), out of which some mice models, like humans, develop symptoms of pneumonia.
The market demand for COVID-19 mouse models is increasing, especially for humanized ACE2 (hACE2) mice, which express human ACE2 in the airway and other epithelia and develop a lethal SARS-CoV infection. However, current supply is limited, as mice model providers do not have readymade populations to meet surging demand. Additionally, due to the pandemic, many research institutions are bound to shut down and are unable to operate normally, which has adversely affected the mice model market.
Inbred mice accounted for the largest share in the mice model market in 2019.
Based on the mice type, the mice model market is categorized into the inbred mice, outbred mice, conditioned/surgically modified mice, hybrid/congenic mice, genetically engineered mice, and spontaneous mutant mice segments. The inbred mice segment accounted for the largest share of the mice model market in 2019. The increasing use of inbred mice for the production of monoclonal antibodies, growing research application of inbred mice in pharmacology and cardiovascular disease studies, are the primary factors driving the growth of this segment.
Oncology Studies accounted for the largest share in the mice model market in 2019
Based on application, the mice model market has been segmented into oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies. The endocrine disease studies segment is further segmented into diabetes and other endocrine metabolic disease. Oncology studies accounted for the largest share of the market in 2019. Increasing prevalence of cancer, a large number of research activities in the field of cancer, and growing implications of mice models in the study of various cancers are expected to drive market growth.
Breeding accounted for the largest share the mice model market in 2019
Based on services, the mice model market is segmented into breeding, quarantine, cryopreservation, rederivation, genetic testing, model in-licensing, and other services (surgical, line rescue, and in vivo pharmacology services). Of all these segments, the breeding services segment accounted for the largest share of the mice model market in 2019. The use of mice models for biomedical and pharmaceutical research has resulted in a growing need for expertise in breeding mutant, transgenic, gene-targeted, and other types of mice. As a result, several companies are providing breeding and other related services to meet growing demand.
CRISPR/Cas9 accounted for the largest share of the mice model market
Based on the type of technology used to create transgenic mice, the mice model market is categorized into the CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies (includes virus/vector-mediated gene transfer, and TALENs & ZFNs) segments. CRISPR is the most widely used technology in the mice model market and contributed to the largest share of the mice model market in 2020. Ease of design, high efficiency, and relatively lower cost have increased the demand for CRISPR-customized mice models.
Cages segment accounted for the largest share of the mice model market
Based on mice care products, the mice model market has been segmented into cages, feed, bedding, and other products (gnotobiotic equipment, water systems, and accessories). In 2019, the cages segment accounted for the largest share of the mice model market. This can be attributed to the availability of a wide range of cages designed for specific research needs and the higher cost of cages compared to other care products.
North America accounted for the largest share of the mice model market in 2019.
Based on the region, the global mice model market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
The major players operating in this market Charles River Laboratories, (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure Bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI Group (China), Ozgene Pty Ltd. (Australia), Harbour Biomed (US) among others
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
